Trending Sources

How the Hell do I Prioritize Work, Blog & Find Balance?

Both Sides of the Table

On blogging I blog because I love it. Mostly I’m Blogging for the Hell of It, Not Blogging to Stay Relevant. link].

HipGeo Launches Updated iPhone Travel Blogging App

socalTECH

networking social blogging travel iphone hipgeoREAD MORE>>.

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

It’s 4.50am. Sunday morning. And I couldn’t sleep. have much on my mind since I just returned from a week on the road. cities. Beers.

Blogging for the Hell of It, Not Blogging to Stay Relevant

Both Sides of the Table

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too.

Why Startups Need to Blog (and what to talk about …)

Both Sides of the Table

Blogs. People often ask me why I started blogging. My suggestion is to blog about your industry. Blog on that topic. Smart.

Biotech Leaders Sign Letter Condemning Trump’s Travel Ban

Xconomy

The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the U.S. to refugees and immigrants from seven Muslim-majority countries. The Jan.

Kentucky Biotech CEO’s Message For McConnell: I’ll Be Muslim, Too

Xconomy

President Trump’s order to bar refugees and immigrants from seven Muslim-majority countries is on temporary hold, and a court hearing later today could eventually force a ruling by the U.S. Supreme Court. Senate. He also wrote that if the Trump administration expanded its policies to include a registry of Muslims, he.

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

Xconomy

They also queried 15 VC firms. To do that, big ag companies will need to source more of their innovations from outside of their own labs.

Sluggish Year for IPOs, But Signs Abound of Post-Election Surge

Xconomy

Uncertainty surrounding this year’s presidential election has kept U.S. Smith anticipates a flurry of IPOs between Thanksgiving.

Bio Roundup: Travel Ban, Pharma in D.C., Biogen Splits, PCSK9 Wins

Xconomy

Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos.

Ex-Xerox CTO Vandebroek Named Chief Operating Officer of IBM Research

Xconomy

When I last spoke to Sophie Vandebroek in December, it was for a kind of exit interview as she prepared to leave her longtime job as Xerox’s CTO and head of its worldwide research organization. Re that last point—she seemed completely unsure. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

IBM 24

Seed-Stage Deals Show Growing Diversity of Agtech Investments

Xconomy

Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments.

Biopharma Leaders Call for Gender Diversity Amid J.P. Morgan Conference

Xconomy

The letter was published Wednesday , on the second to last day of the annual J.P. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy

Xconomy

Still, it’s important to keep these data in perspective. Immune reactions to gene therapy can also stifle its effects.

Report: Demand Media Targets Critical Blog

socalTECH

Santa Monica-based Demand Media , the online content publishing empire run by Richard Rosenblatt, is targeting a blog which has been posting internal documents and criticism of the company. demand media blog critical legal lawsuitThe site appears to have been created by an unhappy, freelance contributor to Demand Media in May of 2010.

Still No Official Word From Biopharma Groups About Trump Travel Ban

Xconomy

Four days after President Donald Trump issued an order to temporarily ban U.S. It released a statement Monday from.

14 for ’17: Key Clinical Data To Watch For Next Year (Part 2)

Xconomy

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here , with looks at key studies in lung cancer, Alzheimer’s disease, asthma, and more. Editor’s note: Ben Fidler and Frank Vinluan contributed to this report.]

Lumina Foundation Gives Odds For Edtech Innovation Under Trump

Xconomy

Bipartisanship hasn’t exactly been the watchword in Washington over the past month as the new Trump administration grapples with stalled nominations, court battles over its travel ban, and investigations of campaign contacts with Russia. students and adults prepare for success in the 21st century.

14 For ’17: Key Clinical Data to Watch For Next Year (Part 1)

Xconomy

[Editor’s note: Alex Lash and Frank Vinluan contributed to this report.] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company.

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

If you’re a fashion product you obviously care about having way more products featured in the vertical trade mags or niche blogs for that sector.

What Should Be on the Next President’s Cybersecurity Agenda?

Xconomy

From a hack of Democratic National Committee e-mails to fears that cyber attackers will attempt to interfere with tomorrow’s election, cybersecurity emerged as a crucial theme in this grueling presidential campaign. asked them what should be prioritized on the next president’s cybersecurity agenda. Reprints | Share: UNDERWRITERS AND PARTNERS.

In Wake Of Infamous Biotech Party, 20 Women Join New Exec Training

Xconomy

A new program to prepare high-ranking women in the biotech industry for corporate board seats has unveiled its first class of 20. and Europe. percent.

How a War on Climate Change Could Restore Economic Growth in America

Xconomy

What’s the biggest, scariest threat facing the United States right now? And I’m going to resist the easy answer that it’s Donald Trump.

Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation

Xconomy

Trump said at last week’s meeting in Washington D.C.,

Trump Slams Drug Companies, Says Medicare “Bidding” Is Coming

Xconomy

Oh, the power of a Donald Trump sound bite. On the campaign trail and as president-elect he has made occasional noises about drug pricing—giving the U.S. Medicare system, the largest buyer of drugs in the world, the right to negotiate prices, for instance. This morning, in his first press conference, Trump went further.

Immunotherapy Clinical Tests Spur Hope, and Plenty of Headaches

Xconomy

Thanks to remarkable results in a small group of patients, including former U.S. Blinding many studies is futile, say clinicians.

Checkpoints In Lung Cancer, and Other Oncology News From Europe

Xconomy

The European Society for Medical Oncology’s annual conference wraps up in Copenhagen today. Here’s a quick roundup of the major news. PARP WALK.

With New Program, DARPA To Encourage Safety “Brakes” For Gene Editing

Xconomy

Drugs that use molecular scissors to snip out or replace defective genes. Altered mosquitoes meant to sabotage entire disease-carrying populations. Both are potential uses of genome editing, which thanks to the CRISPR-Cas9 system has spread throughout the world’s biology labs and is now on the doorstep of the outside world. The U.S.

Interesting New Tech Blog for your Radar Screen

Both Sides of the Table

If you click through to Roger & Mike’s blog you’ll see that this blog post then links to a detailed presentation on the topic.

All In One Place: A New Immuno-Oncology Trial Resource

Xconomy

The infections were turbo-charging the immune system. But those data are impossible to find all in one place. As reporters, we find that frustrating.

Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More

Xconomy

News may be coming out of Washington, DC, at a breakneck pace, but concrete plans regarding the future of the nation’s healthcare system, the FDA, and the pharmaceutical industry have been much slower to materialize. Meanwhile, plans to replace. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

50 Podcasts You Should Be Listening To—and 5 New Ways to Find Them

Xconomy

If you’re not much of a podcast listener and you have a sense that you’re missing out on a lot of great content, you’re absolutely right. But now is a good time to fix that, thanks to a new profusion of listening options. And to get you started, I have a few shows to suggest. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Ex-FDA Commish Califf Gives Props to Patient Groups—With Caveats

Xconomy

” Califf’s brief appearance at a precision medicine conference near San Francisco comes as regulation across industries is in the bullseye of the new Trump administration. President Trump, at a gathering in Washington, told U.S. business leaders today that the federal government could cut regulation “by 75.

BLOGGER ALERT: How to Start a Blog and Make Money Blogging

Tech Zulu Event

In this article you’ll discover how to start a blog that makes money. We’ll primarily be discussing written blogs. Create your blog

SEO 16

ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More

Xconomy

Two years ago at the American Society of Hematology conference, excitement, not blood, was running in the streets of San Francisco.

After “Hubris” and Its HCV Collapse, Can Vertex Avoid Same Mistakes?

Xconomy

Its experimental drug PSI-7977 had quickly cleared the virus from 40 patients , with minimal side effects, and they had stayed infection-free.

Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More

Xconomy

Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick.

News 19

Some Thoughts on Twitter as a Micro-Blogging Tool

Both Sides of the Table

It turns out that it works fine how I did it with the web version of Twitter but not with mobile. 1/ Twitter started off positioned as a micro-blogging platform but in the end became more of an RSS reader. The post Some Thoughts on Twitter as a Micro-Blogging Tool appeared first on Bothsides of the Table. Needed Twitter functionality.

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA

Xconomy

Heather and Jessica Tomko will tell you that they’re nothing alike. They’ve got different interests, different tastes in movies, television, and music.

Bio Roundup: Trump News, Anthem’s Stand, Diversity by 2056 & More

Xconomy

It was a wild week in biotech and on Capitol Hill. A new study showed it may take another 40 years to achieve gender diversity in life sciences. Tensions continued to mount between drugmakers and payers over the rising costs of rare disease drugs. And a group of biotechs led by Jounce Therapeutics were the first to test the IPO market in 2017.